论文部分内容阅读
目的 观察和评价人工气腹辅助治疗耐多药肺结核 (MDR- PTB)的疗效。方法 经人工气腹加药物治疗 MDR- PTB 2 2例 ,与单纯药物治疗 2 4例进行对照。结果 经人工气腹治疗组疗程结束时痰菌阴转率 86 .4% ,病灶吸收显效率 90 .9% ,空洞闭合率 89.5 % ,均显著高于单纯药物对照组的 33.3%、37.5 %及 35 .3% (P<0 .0 1) ,且无明显并发症及副反应。经最长 3年、最短 1年随访 ,治疗组和对照组细菌学复发率分别为 5 .3和 5 0 .0 ,差异有显著性意义 (P<0 .0 5 )。结论 人工气腹加化疗治疗 MDR- PTB,疗效显著优于单纯化疗 ,有推广前景
Objective To observe and evaluate the efficacy of artificial pneumoperitoneum in the treatment of multidrug-resistant pulmonary tuberculosis (MDR-PTB). Methods Two cases of MDR-PTB were treated with artificial pneumoperitoneum plus drugs, compared with 24 cases with simple drug therapy. Results After pneumoperitoneum treatment group finished, the sputum negative conversion rate was 86.4%, the effective absorption rate of the lesion was 90.9% and the void closure rate was 89.5%, which were significantly higher than those of the simple drug control group (33.3%, 37.5%) 35.3% (P <0.01), and no obvious complications and side effects. After a maximum of 3 years and a minimum follow-up of 1 year, the bacteriological recurrence rates of the treatment group and the control group were respectively 5.3% and 5.0%, with significant difference (P <0.05). Conclusions Artificial pneumoperitoneum combined with chemotherapy in the treatment of MDR-PTB is significantly better than chemotherapy alone, with promotion prospects